Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: mangery who wrote (545)	3/7/2005 3:30:41 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

If CTI is able to prove to the satisfaction of FDA's statisticians, that the drug really is non-inferior, I believe that the chance for approval should be relatively good. Say, in the 75 % range or so. Because, I see no good reason for FDA to deny a drug like this market access, if the drug is not inferior to what is today available. No doubt its use will bring QoL-benefits, compared to the drugs that are available today. But, as we don't know how Xyotax fared from an efficacy point of view, such handicapping is meaningless today. Erik